September 18, 2019 10:46 AM EDTUpdated 01:11 PM

vTv Therapeutics reports additional positive PhII data; Shanghai Henlius prices $410 million IPO at bottom of range

Kathy Wong

Editor

→ vTv Therapeutics — focused on the development of oral small molecule drug candidates — has unveiled additional positive data from its Phase II Simplici …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

vTv Therapeutics reports additional positive PhII data; Shanghai Henlius prices $410 million IPO at bottom of range

Kathy Wong

Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Will CRISPR matter?

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

vTv Ther­a­peu­tics re­ports ad­di­tion­al pos­i­tive PhII da­ta; Shang­hai Hen­lius prices $410 mil­lion IPO at bot­tom of range

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

vTv Therapeutics reports additional positive PhII data; Shanghai Henlius prices $410 million IPO at bottom of range